PDF factsheet
      Z

immune checkpoint inhibition in Head and neck cancer for all type of patients, clinical trials results

nivolumab versus standard treatment
Checkmate-141, 2016
NCT02105636
nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks
versus
standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab).
patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapyopen-label
pembrolizumab versus standard treatment
KEYNOTE-040,
NCT02252042
pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle
versus
standard treatment (methotrexate, docetaxel or cetuximab)
patients with recurrent or metastatic head and neck squamous cell canceropen-design

  Options


in first

in second

  Filter